Your browser doesn't support javascript.
loading
Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial.
Wong, James S H; Nikoo, Mohammadali; Westenberg, Jean N; Suen, Janet G; Wong, Jennifer Y C; Krausz, Reinhard M; Schütz, Christian G; Vogel, Marc; Sidhu, Jesse A; Moe, Jessica; Arishenkoff, Shane; Griesdale, Donald; Mathew, Nickie; Azar, Pouya.
Afiliação
  • Wong JSH; Addictions and Concurrent Disorders Research Group, Institute of Mental Health, Department of Psychiatry, The University of British Columbia, 430-5950, David Strangway Building, Vancouver, BC, V6T 1Z3, Canada. james.wong@ubc.ca.
  • Nikoo M; Addictions and Concurrent Disorders Research Group, Institute of Mental Health, Department of Psychiatry, The University of British Columbia, 430-5950, David Strangway Building, Vancouver, BC, V6T 1Z3, Canada.
  • Westenberg JN; Addictions and Concurrent Disorders Research Group, Institute of Mental Health, Department of Psychiatry, The University of British Columbia, 430-5950, David Strangway Building, Vancouver, BC, V6T 1Z3, Canada.
  • Suen JG; Addictions and Concurrent Disorders Research Group, Institute of Mental Health, Department of Psychiatry, The University of British Columbia, 430-5950, David Strangway Building, Vancouver, BC, V6T 1Z3, Canada.
  • Wong JYC; Addictions and Concurrent Disorders Research Group, Institute of Mental Health, Department of Psychiatry, The University of British Columbia, 430-5950, David Strangway Building, Vancouver, BC, V6T 1Z3, Canada.
  • Krausz RM; Addictions and Concurrent Disorders Research Group, Institute of Mental Health, Department of Psychiatry, The University of British Columbia, 430-5950, David Strangway Building, Vancouver, BC, V6T 1Z3, Canada.
  • Schütz CG; Behavioral Reward Affect + Impulsivity Neuroscience Lab, Institute of Mental Health, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.
  • Vogel M; Division of Addictive Disorders, University of Basel Psychiatric Hospital, Wilhelm Klein-Strasse 27, 4002, Basel, Switzerland.
  • Sidhu JA; Department of Psychiatry, University of British Columbia & Vancouver General Hospital, Vancouver, BC, Canada.
  • Moe J; Department of Emergency Medicine, University of British Columbia & Vancouver General Hospital, Vancouver, BC, Canada.
  • Arishenkoff S; BC Centre for Disease Control, Provincial Health Services Authority, Vancouver, BC, Canada.
  • Griesdale D; Department of Medicine, University of British Columbia & Vancouver General Hospital, Vancouver, BC, Canada.
  • Mathew N; Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia & Vancouver General Hospital, Vancouver, BC, Canada.
  • Azar P; Department of Psychiatry, University of British Columbia & Vancouver General Hospital, Vancouver, BC, Canada.
Addict Sci Clin Pract ; 16(1): 11, 2021 02 12.
Article em En | MEDLINE | ID: mdl-33579359
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Síndrome de Abstinência a Substâncias / Tratamento de Substituição de Opiáceos / Combinação Buprenorfina e Naloxona / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Eixos temáticos: Pesquisa_clinica Base de dados: MEDLINE Assunto principal: Síndrome de Abstinência a Substâncias / Tratamento de Substituição de Opiáceos / Combinação Buprenorfina e Naloxona / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Female / Humans / Male País como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article